1. Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies.
- Author
-
Cristina Marchini, Maura Montani, Georgia Konstantinidou, Rita Orrù, Silvia Mannucci, Giorgio Ramadori, Federico Gabrielli, Anna Baruzzi, Giorgio Berton, Flavia Merigo, Stefania Fin, Manuela Iezzi, Brigitte Bisaro, Andrea Sbarbati, Massimo Zerani, Mirco Galiè, and Augusto Amici
- Subjects
Medicine ,Science - Abstract
BackgroundMounting clinical and experimental evidence suggests that the shift of carcinomas towards a mesenchymal phenotype is a common paradigm for both resistance to therapy and tumor recurrence. However, the mesenchymalization of carcinomas has not yet entered clinical practice as a crucial diagnostic paradigm.Methodology/principal findingsBy integrating in silico and in vitro studies with our epithelial and mesenchymal tumor models, we compare herein crucial molecular pathways of previously described carcinoma-derived mesenchymal tumor cells (A17) with that of both carcinomas and other mesenchymal phenotypes, such as mesenchymal stem cells (MSCs), breast stroma, and various types of sarcomas. We identified three mesenchymal/stromal-signatures which A17 cells shares with MSCs and breast stroma. By using a recently developed computational approach with publicly available microarray data, we show that these signatures: 1) significantly relates to basal-like breast cancer subtypes; 2) significantly relates to bone metastasis; 3) are up-regulated after hormonal treatment; 4) predict resistance to neoadjuvant therapies.Conclusions/significanceOur results demonstrate that mesenchymalization is an intrinsic property of the most aggressive tumors and it relates to therapy resistance as well as bone metastasis.
- Published
- 2010
- Full Text
- View/download PDF